|
|
5 May 2017 |
Advanced Medical Solutions Group plc
(“AMS”, the “Company” or the “Group”)
Director/PDMR and PCA Shareholding
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), a leading developer and manufacturer of advanced products for the global surgical and advanced wound care markets, announces that the Trust which manages the Deferred Share Bonus Plan (“Plan”) on behalf of the employees of AMS has purchased ordinary shares of 5 pence each (“Ordinary Shares”) on 2 May 2017, at a price of 264.07p on behalf of Chris Meredith, Mary Tavener, Simon Coates, Rose Guang, Eddie Johnson, Becky Walmsley and Jeff Willis (“PDMRs”) as part of the Deferred Share Bonus Plan and, under the terms of the Plan, these shares will be held in trust on their behalf.
Following these transactions the beneficial ownership of the PDMRs is as follows:
|
Director/PDMR |
Date purchased |
Shares purchased |
Resultant holding |
|
Chris Meredith Chief Executive Officer |
2 May 2017 |
2,186 |
1,192,508 |
|
Mary Tavener Chief Financial Officer |
2 May 2017 |
1,684 |
1,829,813 |
|
Simon Coates PDMR |
2 May 2017 |
4,382 |
79,481 |
|
Rose Guang PDMR |
2 May 2017 |
7,224 |
36,059 |
|
Eddie Johnson PDMR |
2 May 2017 |
7,157 |
52,195 |
|
Becky Walmsley PDMR |
2 May 2017 |
2,381 |
3,469 |
|
Jeff Willis PDMR |
2 May 2017 |
5,226 |
130,085 |
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||
|
a) |
Name: Chris Meredith |
||||
2. |
Reason for the notification |
||||
|
a) |
Position/status: Director/PDMR |
||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||
|
b) |
Nature of the transactions: · Purchase of 2,186 Ordinary Shares as part of the Deferred Share Bonus Plan on 2 May 2017 |
||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a |
||||
|
e) |
Date of the transaction: 02/05/2017 |
||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||
|
a) |
Name: Mary Tavener |
||||
2. |
Reason for the notification |
||||
|
a) |
Position/status: Director/PDMR |
||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||
|
b) |
Nature of the transactions: · Purchase of 1,684 Ordinary Shares as part of the Deferred Share Bonus Plan on 2 May 2017 |
||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a |
||||
|
e) |
Date of the transaction: 02/05/2017 |
||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||
|
a) |
Name: Simon Coates |
||||
2. |
Reason for the notification |
||||
|
a) |
Position/status: Director/PDMR |
||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||
|
b) |
Nature of the transactions: · Purchase of 4,382 Ordinary Shares as part of the Deferred Share Bonus Plan on 2 May 2017 |
||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a |
||||
|
e) |
Date of the transaction: 02/05/2017 |
||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||
|
a) |
Name: Rose Guang |
||||
2. |
Reason for the notification |
||||
|
a) |
Position/status: Director/PDMR |
||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||
|
b) |
Nature of the transactions: · Purchase of 7,224 Ordinary Shares as part of the Deferred Share Bonus Plan on 2 May 2017 |
||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a |
||||
|
e) |
Date of the transaction: 02/05/2017 |
||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||
|
a) |
Name: Eddie Johnson |
||||
2. |
Reason for the notification |
||||
|
a) |
Position/status: Director/PDMR |
||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||
|
b) |
Nature of the transactions: · Purchase of 7,157 Ordinary Shares as part of the Deferred Share Bonus Plan on 2 May 2017 |
||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a |
||||
|
e) |
Date of the transaction: 02/05/2017 |
||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||
|
a) |
Name: Becky Walmsley |
||||
2. |
Reason for the notification |
||||
|
a) |
Position/status: Director/PDMR |
||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||
|
b) |
Nature of the transactions: · Purchase of 2,381 Ordinary Shares as part of the Deferred Share Bonus Plan on 2 May 2017 |
||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a |
||||
|
e) |
Date of the transaction: 02/05/2017 |
||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||
|
a) |
Name: Jeff Willis |
||||
2. |
Reason for the notification |
||||
|
a) |
Position/status: Director/PDMR |
||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||
|
b) |
Nature of the transactions: · Purchase of 5,226 Ordinary Shares as part of the Deferred Share Bonus Plan on 2 May 2017 |
||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a |
||||
|
e) |
Date of the transaction: 02/05/2017 |
||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
– End –
For further information, please visit www.admedsol.com or contact:
|
Advanced Medical Solutions Group plc |
Tel: +44 (0) 1606 545508 |
|
Chris Meredith, Chief Executive Officer Mary Tavener, Chief Financial Officer |
|
|
|
|
|
Consilium Strategic Communications |
Tel: +44 (0) 20 3709 5700 |
|
Mary-Jane Elliott / Jonathan Birt / Matthew Neal / Hendrik Thys |
AMS@consilium-comms.com |
|
|
|
|
Investec Bank PLC (NOMAD & Broker) |
Tel: +44 (0) 20 7597 5970 |
|
Daniel Adams / Patrick Robb |
|
About Advanced Medical Solutions Group plc – see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and advanced wound care markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of wound care products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it sells under white label as well as its own brand ActivHeal®, and surgical tissue adhesives, sutures and haemostats, which markets under its own brands; LiquiBand® and RESORBA®.
AMS’s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 70 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Company has 600 employees. For more information, please see www.admedsol.com.
This information is provided by RNS
END
DSHBRGDUBGGBGRU